Seattle Genetics Commits To Simultaneous Confirmatory Trials For Adcetris
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves the antibody-drug conjugate for late stage Hodgkins lymphoma and systemic anaplastic large cell lymphoma Aug. 19.
You may also be interested in...
Randomization Required: Liver Signal Necessitated Kadcyla Trial With Control Arm
A pivotal trial with a control arm was necessary to evaluate a hepatotoxicity signal with Genentech’s Kadcyla, helping to derail a bid for accelerated approval based on a single-arm Phase II trial. Genentech’s strategy of running trials in different lines of treatment concurrently enabled a quick strategy shift as an ongoing controlled Phase III trial in another line was amended to meet FDA’s regulatory requests.
Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.
Ambrx Links Its ADC Technology To Japan’s Astellas In Oncology Deal
The San Diego biotech has landed another large pharma partner for its antibody-drug conjugation technology as the space continues to attract interest.